In the BioHarmony Drug Report Database
Halobetasol
Bryhali, Lexette, Ultravate (halobetasol) is a small molecule pharmaceutical. Halobetasol was first approved as Bryhali on 1990-12-17. It is used to treat facial dermatoses, foot dermatoses, hand dermatoses, inflammation, and leg dermatoses amongst others in the USA. Halobetasol propionate’s patents are valid until 2036-11-30 (FDA).
Trade Name
|
Bryhali, Lexette, Ultravate |
|---|---|
Common Name
|
halobetasol |
ChEMBL ID
|
CHEMBL1201360 |
Indication
|
facial dermatoses, foot dermatoses, hand dermatoses, inflammation, leg dermatoses, pruritus, scalp dermatoses |
Drug Class
|
Image (chem structure or protein)